ARTL vs. RNAZ, TFFP, GTBP, CLVR, THAR, DRUG, XCUR, ALZN, CYCC, and NEXI
Should you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include TransCode Therapeutics (RNAZ), TFF Pharmaceuticals (TFFP), GT Biopharma (GTBP), Clever Leaves (CLVR), Tharimmune (THAR), Bright Minds Biosciences (DRUG), Exicure (XCUR), Alzamend Neuro (ALZN), Cyclacel Pharmaceuticals (CYCC), and NexImmune (NEXI). These companies are all part of the "pharmaceutical preparations" industry.
TransCode Therapeutics (NASDAQ:RNAZ) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, community ranking, profitability, earnings, risk, media sentiment, institutional ownership and valuation.
TransCode Therapeutics has a beta of -0.36, indicating that its share price is 136% less volatile than the S&P 500. Comparatively, Artelo Biosciences has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500.
Artelo Biosciences is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.
0.9% of Artelo Biosciences shares are held by institutional investors. 1.5% of TransCode Therapeutics shares are held by insiders. Comparatively, 6.9% of Artelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Artelo Biosciences had 1 more articles in the media than TransCode Therapeutics. MarketBeat recorded 7 mentions for Artelo Biosciences and 6 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 0.07 beat Artelo Biosciences' score of -0.20 indicating that Artelo Biosciences is being referred to more favorably in the news media.
TransCode Therapeutics' return on equity of -73.82% beat Artelo Biosciences' return on equity.
Artelo Biosciences received 31 more outperform votes than TransCode Therapeutics when rated by MarketBeat users. However, 87.50% of users gave TransCode Therapeutics an outperform vote while only 73.08% of users gave Artelo Biosciences an outperform vote.
TransCode Therapeutics presently has a consensus price target of $3.00, indicating a potential upside of 152.10%. Artelo Biosciences has a consensus price target of $5.00, indicating a potential upside of 220.51%. Given TransCode Therapeutics' higher probable upside, analysts plainly believe Artelo Biosciences is more favorable than TransCode Therapeutics.
Summary
Artelo Biosciences beats TransCode Therapeutics on 11 of the 13 factors compared between the two stocks.
Get Artelo Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Artelo Biosciences Competitors List
Related Companies and Tools
